Novan Inc. NOVN is a pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . Novan reported a total revenue of $3.2 million for the first quarter of 2023. The company continues to prepare ...

Novan’s antiviral SB206 has failed to beat placebo in two phase 3 trials in patients with molluscum contagiosum. The setback wiped 74% off Novan’s value and left its cash runway looking precariously ...

Please provide your email address to receive an email when new articles are posted on . Novan has submitted a new drug application to the FDA for the marketing authorization of berdazimer gel 10.3% ...

After reporting disappointing news from an important late-stage clinical trial, shares of Novan (NASDAQ: NOVN), a clinical-stage biotech focused on dermatology, plunged by more than 75% in ...

Nanotechnology company Novan has raised $6 million in financing as the startup continues development of its nitric oxide technology into a bacteria-fighting tool. Novan was formed in 2006, spun out of ...

Less than six months after Ligand Pharmaceuticals swooped in to buy Novan’s assets following the latter company’s bankruptcy, the purchase has paid off with an FDA approval. Late Friday, the FDA ...

DURHAM, N.C.--(BUSINESS WIRE)--Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that it has secured ...

Novan's consolidated results for the three months ended March 31, 2022 includes 20 days of activity from its Commercial Operations business unit, based on the EPI Health acquisition closing date. As ...

Novan reported top-line results from its two phase 3 trials that were testing its lead compound -- called SB204 -- as a hopeful treatment for acne vulgaris. The first trial was called NI-AC302. The ...